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Abstract 
Ethylphenidate is a stimulant novel psychoactive substance that is an analogue of 
the prescription drug methylphenidate (Ritalin ®. Methylphenidate is used commonly 
for the treatment of attention deficit hyperactivity disorder. Due to its stimulant effects 
ethylphenidate is being abused. There is a single case report of a death associated 
with ethylphenidate in Germany, and a case series of 19 deaths in the East of 
Scotland, but otherwise, the contribution of ethylphenidate to death is poorly 
documented. We report the analytical results of 7 cases (between February 2013 
and January 2015) in which ethylphenidate was detected and quantitated with a 
validated liquid chromatography tandem mass spectrometry method (LC-MS/MS). 
The individuals (all male) ranged in age from 23 to 49 years (median 25 years). The 
concentration of ethylphenidate in the cases ranged from 0.026 mg/L to 2.18 mg/L in 
unpreserved post-mortem femoral blood. Only one case had ethylphenidate present 
as a sole drug.  All other cases had at least 2 other drug classes present 
(benzodiazepines, heroin, methadone antipsychotics, other new psychoactive 
compounds). Ethylphenidate toxicity was the sole contribution to the cause of death 
in one case. Hanging was the cause of death in 2 cases, with the other 4 cases 
being reported as having occurred due to mixed drug toxicity. These data will further 
help with the interpretation of post-mortem ethylphenidate levels. 
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1. Introduction 
Ethylphenidate [ethyl 2-phenyl-2-(piperidin-2-yl) acetate; ritalinic acid ethyl ester; 
CAS: 57413-43-1 (base), 19716-79-1 (Hydrochloride) [Fig.1] is a racemic (+/- 
isomers) stimulant drug that is an analogue of the prescription drug methylphenidate 
(commonly known as Ritalin®). Ethylphenidate was first mentioned in the literature in 
1961 [1] and was patented in 2003 [2] for the potential treatment of ADHD with 
reduced abuse potential when compared to methylphenidate.  The abuse of 
methylphendiate having been recorded from the 1960’s [3]. The first evidence of 
ethylphenidate abuse was in 2011 when it was officially reported to the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) after being found on 
sale in UK “headshops” [4]. Due to the reported abuse of ethylphenidate it was 
controlled in the UK under a temporary class order in April 2015 [5].    
To date ethylphenidate has been sold in head shops and online under various 
names including “Nopaine”, “Gogaine”, “Ching” and “Burst (duck)” [6, 7], in various 
forms (powder, crystals and “pellets” (25 mg or 50 mg)) [7, 8], with a “recommended” 
oral dose of between 25 - 50 mg [8]. For insufflation users have reportedly used 
between 10 and 100 mg [9]. The effects of ethylphenidate that have been reported 
by users (stimulation, euphoria, an increase in focus, improved concentration, 
increased sociableness, empathy [8, 9]) are similar to those observed with other 
stimulants [10]. These “positive” effects are counteracted with the side-effects 
(anxiety; paranoia; hallucinations; increased heart rate blood pressure and body 
temperature; peripheral vasoconstriction; insomnia; sweating and nasal pain on 
insufflation [7-9, 11]) that are again commonly seen with other abuse stimulants [10]. 
The pharmacokinetics of ethylphenidate are unclear but information from user 
reports suggest that the mean onset time for ethylphendiate is ~ 13 min (range 0 – 
35 min; n = 32) for nasal insufflation, and ~ 23 min (range 5 – 31 min; n = 8) for oral 
administration [8]. The mean duration of the effects were 117 min for all routes of 
administration (range 15 – 300 min; n = 29) however this is complicated by redosing. 
The half-life (t½) of (-)ethylphenidate can be estimated from the methylphenidate and 
ethanol human studies and is between 0.5 – 4.7h (mean ~1.25 h) n = 8 [12] although 
this may be complicated by the concomitant presence of methylphenidate and 
ethanol both of which are known to inhibit the metabolism of ethylphenidate and 
there may be also differences in metabolism of the (-) and (+) isomers of 
ethylphenidate [12-14]. Due to lack of clinical studies case reports are important to 
understand the toxicity of new psychoactive substances (NPS) such as 
ethylphenidate.  
In this paper we report the toxicological findings of 7 cases where ethylphenidate 
was detected and quantitated and also for the first time report a death that was 
solely attributable to ethylphenidate. Detection and quantitation of ethylphenidate 
were carried out using liquid chromatography with tandem mass spectrometry (LC-
MS/MS). These cases add to the body of knowledge of ethylphenidate and will help 
in the interpretation of cases where ethylphenidate is detected and quantitated.   
 
 
 
 2. Methods 
2.1 Initial Toxicological Screening 
All submitted toxicological samples underwent systematic toxicological analysis 
incorporating analysis for volatiles using headspace gas chromatography with flame 
ionisation detection (HS-GC-FID) and analysis for drugs by both gas 
chromatography-mass spectrometry (GC-MS) and liquid chromatography with 
tandem mass spectrometry (LC-MS/MS). The drugs were matched to both in-house 
(constructed from reference standards) and commercial libraries (NIST05 and 
SWGDRUG). Following confirmation of the presence of a drug the femoral blood 
drug levels were quantitated using LC-MS/MS.  
2.2 Quantitation of ethylphenidate  
2.2.1 Reagents and materials 
Certified standards for ethylphenidate and d3-methylphenidate were purchased from 
LGC Standards (Teddington, UK). Methanol, chloroform, isopropanol, hydrochloric 
acid, 35% ammonia solution and glacial acetic acid were purchased from Fisher 
Scientific (Loughborough, UK). Potassium dihydrogen orthophosphate was 
purchased from BDH (Poole, UK). Strata Screen-C solid phase extraction (SPE) 
cartridges were purchased from Phenomenex (Macclesfield, UK). Blank equine 
serum was purchased from TCS Biosciences (Buckingham, UK). 
2.2.2 Standards, calibrators, control and internal standard preparation 
A stock solution of ethylphenidate was prepared at a concentration of 1 mg/mL in 
methanol and stored at -20 °C. A calibration curve between 0.005 – 1.00 mg/L was 
prepared in blank equine serum. The internal standard (d3-methylphenidate) was 
prepared at a concentration of 2 mg/L in methanol and stored at -20 °C. Calibrator 
materials were prepared prior to each extraction. If required, post-mortem blood 
samples were diluted in blank equine serum to fit into the calibration range. In-house 
quality control material was prepared from a separate stock solution of 
ethylphenidate at levels of 0.150 mg/L and 0.750 mg/L. 
2.2.3 Extraction method for biological specimens 
The extraction method was based on a standard solid phase extraction procedure 
[15]. Briefly, 1 mL of the standard/control/biological sample was added to a 10 mL 
glass tube and spiked with 200 μL of internal standard (d3-methylphenidate). 1 mL of 
phosphate buffer (0.1 M potassium dihydrogen orthophosphate in deionised water, 
pH 6.0) followed by 2 mL of deionised water was added to all tubes. Tubes were 
briefly vortexed and then sonicated for 10 minutes. After centrifugation at 3500 rpm 
for 8 minutes, the supernatant was added to Phenomenex Strata Screen-C solid 
phase extraction columns (pre-conditioned with methanol, deionised water and 0.1 M 
phosphate buffer) and eluted at low speed (1 - 2 mL/min). After washing with 
deionised water, 0.1 M hydrochloric acid and methanol, samples were eluted at low 
speed (1 - 2 mL/ min) with 3 mL of elution buffer (800 mL chloroform, 200 mL 
isopropanol, 3 mL 35% ammonia solution) into 10 mL glass tubes. Samples were 
concentrated under nitrogen and reconstituted with 100µl of 10% methanol and 
transferred to a liquid chromatography vial for injection. 
2.2.4 Instrumentation and LC-MS/MS parameters 
Quantitative analysis of ethylphenidate was performed with a novel method using an 
Agilent Technologies 1200 Series HPLC system coupled with an Agilent 
Technologies 6460 Triple Quadrupole mass spectrometer. Agilent MassHunter 
Workstation Software B.03.01 was used for data analysis. Separation was carried 
out on an Agilent Zorbax SB-C18 30 mm × 2.1 mm column (particle size: 3.5 μm). A 
gradient elution program was applied at a flow rate of 0.6 mL/min with eluent A 
consisting of 0.1 % glacial acetic acid in deionised water and eluent B consisting of 
0.1 % glacial acetic acid in methanol. Gradient elution was 0 – 1.5 min 10  100% 
B; 1.5 – 2.8 min 100% B; 2.8 – 4 min 100  10% B total run time of 4 minutes. 
Column temperature = 30 °C, injection volume = 2 µL. The mass spectrometer was 
operated in multiple reaction monitoring (MRM) mode using positive electrospray 
ionisation (ESI). Drying gas (nitrogen) temperature was set to 350 °C, gas flow rate 
to 5 L/min, nebuliser pressure to 45 psi, capillary voltage to 3500 V, collision energy 
(CE) to 20 V; dwell time to 30 ms; Vfr was set to 110 V for ethylphenidate and 100 V 
for the internal standard (d9-methylphenidate). The following ion transitions and 
retention times were observed:  ethylphenidate (m/z 248/84 & 248/56), 0.976 min 
and the internal standard d9-methylphenidate (m/z 243/93 & 243/61), 0.720 min 
(quantitation ions underlined).   
2.2.5 Method validation and matrix effects 
The LC-MS/MS method for ethylphenidate quantitation was validated in plasma 
using the conditions previously described and according to the guidelines of Peters 
et al. [16]. Standard calibration curves for ethylphenidate in equine serum were linear 
from 0.005 – 1.00 mg/L with an r2 > 0.999. Using quality control samples of 0.150 
mg/L and 0.750 mg/L the method was shown to be both accurate and precise 
(interday (n=5) and intraday (n=30)) within acceptable ranges of ± 15%. The limit of 
detection (LOD) was found to be 0.002 mg/L and the lower limit of quantitation 
(LOQ) was found to be 0.005 mg/L. The matrix effects were evaluated by the 
methods of Matuszewski et al.  [17] at both 0.150 mg/L and 0.750 mg/L and although 
ion suppression/enhancement was observed the results were within the accepted ± 
15%. 
 
3. Results and Discussion 
This study reports the quantitative results of 7 post-mortem cases (between 
February 2013 and January 2015) across England in which ethylphenidate was 
detected and quantitated (table 1) using a validated LC-MS/MS method. These 
cases include a death where ethylphenidate was the sole drug detected, 2 cases in 
which drugs were not related to the cause of death (in this case hanging), and 4 
cases where multiple drug toxicity was registered as the cause of death. The age 
range of the 7 individuals (all male) was 23 to 49 years (median 25 years), which is 
similar to the age ranges (20 – 54 years [6]; 32 & 38 years [18]) that was seen in 
previous cases reporting ethylphenidate deaths.  
Table 2 lists the three previous publications in the literature that have given both 
analytically confirmed clinical and post-mortem concentrations of ethylphenidate. 
This gives some idea of the concentrations that can be observed in various case 
types. In the sole clinical case the measured blood concentration of ethylphenidate 
was 0.24 mg/L, 20 hours after a reported use of 500mg of ethylphenidate [7]. In post-
mortem samples that were not drug related (such as hanging and electrocution) the 
concentrations of ethylphenidate were 0.010 mg/L to >2.0 mg/L. In the two highest 
concentrations (1.3 mg/L  and >2.0 mg/L) the causes of death were hanging (this 
study) and “a complication of the deceased’s intravenous drug administration, 
namely acute haemorrhage related to left groin abscess” [6]. They were not 
significantly lower than the sole case of ethylphenidate toxicity (2.2 mg/L) with no 
other drugs from this study (table 1). This with the other results presented in table 2 
suggest that there may be a significant overlap between “therapeutic” and “fatal” 
levels of ethylphenidate.  
The large variations of concentrations of ethylphenidate and their effects are likely to 
be both from natural variation in drug susceptibility and also tolerance to 
ethylphenidate, for example in one case where a user was reported to be taking up 
to fifty 20 mg pills per day [11]. Death due to ethylphenidate may also not be directly 
related to blood drug concentration and as with other stimulants ethylphenidate may 
cause cardiac damage [19]. In the first death cases related to ethylphenidate 
reported by Krueger et al., it was suspected that the cardiovascular side effects may 
have contributed to the death especially as the deceased was found to have mitral 
valve endocarditis [18]. An added complication is that the concentrations of 
ethylphenidate may have been underreported due to instability, although 
ethylphenidate has not been subject to stability studies in blood or plasma, 
methylphenidate has been shown to be unstable in both blood and plasma due to 
hydrolysis by blood esterases [20-23]. From the results of these studies it appears 
that the best method of maintaining stability of ethylphenidate is most likely to be via 
storage at temperatures less than 4°C and in sodium fluoride (NaF) containing tubes 
[24] although this would need to be confirmed with stability studies. Finally it is a 
possibility post-mortem redistribution may have altered the drug concentrations in 
femoral blood after death [25]. The case results of ethylphenidate cases suggest that 
as with all toxicological cases the drug concentrations should be interpreted with the 
full knowledge of the case circumstances where possible. It is interesting to note that 
in both this study and the study by Parks et al., a large number of individuals using 
ethylphenidate were also opiate abusers (heroin) 11 of 19 cases [6]; 3 of 7 cases 
[this study], overall >50% between the two studies. Parks et al., also indicate that in 
9 of the 17 reported cases ethylphenidate was being injected. Previous studies have 
utilised internet forum case reports to investigate the routes of administration of 
ethylphenidate [8, 9]. In the case reports ethylphenidate is most commonly 
insufflated (52.5%) followed by multiple routes (16.7%), oral ingestion (11.6%) and 
intravenous injection (9.6%). Minor routes include rectal insertion, sublingual 
insertion, smoking and intramuscular injection [8].  
One of the major concerns with ethylphenidate that has been highlighted by the 
internet forum case studies is users reporting “a persistent impulse to redose” with 
31 of 44 users redosing with ethylphenidate one or more times. The long term abuse 
potential is hard to determine without more detailed studies however the 
pharmacology of ethylphenidate suggests that there is a significant risk of abuse. 
Ethylphenidate exists as a racemic mixture with – (l) and + (d) isomers, 
pharmacological studies have shown that the individual isomers have different 
pharmacological activity [26, 27]. In vitro studies on human monoamine transporters 
5-HT (SERT), noradrenaline (NET) and dopamine (DAT) expressed in HEK293 cells 
evaluated the pharmacology of the racemic mixture (-/+) and the individual isomers 
have shown that, (+) ethylphenidate exhibited potent effects on DAT uptake inhibition 
(Ki – 27 nM), (-/+) ethylphenidate was slightly less potent (Ki – 95 nM) and (-) 
ethylphenidate was inactive (1730 nM). Both (+) and (-/+) ethylphenidate inhibited 
NET uptake although with less potency than DAT inhibition (Ki – 230 nM and 319 nm 
respectively) again (-) ethylphenidate was inactive [26].  None of the isomers had 
any functional activity on either dopamine 1-3 or 5-HT1A,2A,2C receptors or on SERT 
uptake inhibition [26]. In vivo studies on mice showed that both (+) and (-/+) 
ethylphenidate cause significant increases in motor activity compared to control, 
when mice were administered 10mg/kg (i.p.) of ethylphenidate with (-) 
ethylphendidate showing again that it is inactive by having no significant effect on 
motor activity compared to control [26, 27]. The increase in locomotor activity is 
commonly used, among other in vivo tests (such as self-stimulation) as an indicator 
of abuse potential [28]. The increase in motor activity suggesting that ethylphenidate 
has abuse potential, further evidence can be found from the ratio of DAT/SERT 
inhibition with higher ratios thought to indicate a higher abuse potential [29]. From in 
vitro data [26] both (-/+) and (+) ethylphenidate have a DAT/SERT ratio of >105 
indicating a high abuse potential, this is backed up by case studies where users of 
ethylphenidate feel the need to redose [8, 9].   
Ethylphenidate, like its analogue methylphenidate has been shown to be initially 
metabolised to the pharmacologically inactive ritalinic acid (in phase I) by 
carboxylesterase 1C (hCES1c) [30], one of a group of carboxylesterases that 
commonly metabolise ester containing drugs (such as heroin and cocaine) [31]. 
Although full metabolic studies into ethylphenidate have not been carried out to date 
it is expected that ethylphenidate would follow a similar metabolic profile to 
methylphenidate [32]. The putative metabolic profile of ethylphenidate is shown in 
figure 1.  
The first deaths that were related to ethylphenidate showed that ritalinic acid was 
detected in urine (both cases) along with methylphenidate (one case) and in blood 
(along with ethylphenidate) in both cases [18], the ritalinic acid in case 1 was 2.14 
mg/L compared to 0.023 mg/L ethylphenidate. In case 2 ritalinic acid was 0.943 mg/L 
compared to 0.110 mg/L ethylphenidate. The high levels of ritalinic acid compared to 
ethylphenidate with no presence of methylphenidate or ethanol allow the 
confirmation of ethylphenidate as the drug that was initially taken and was not 
present as a metabolite. The fact that the metabolic interaction of ethanol and 
methylphenidate leads to the formation of ethylphenidate by transesterification was 
discovered following post-mortem analysis of two fatal overdoses [33]. Further 
controlled human studies were then carried out to investigate this phenomenon. The 
studies found that predominantly the inactive (–)ethylphenidate is formed, with the 
maximum amount of the (+)ethylphenidate only ever being 10% of the Cmax 
concentration of (–)ethylphenidate, with (-)ethylphenidate only being around 10% of 
the concentration of methylphenidate plasma concentrations when concomitantly 
administered with ethanol [12-14]. The use of both enantiomer specific 
chromatography [34] and the levels of ethylphenidate detected with “normal” 
chromatography allow determination of the source of ethylphenidate. The studies 
[12-14] also showed that significant increases (~40% of mean) in the Cmax 
concentration of methylphenidate were observed when methylphenidate is combined 
with ethanol, this adds confirmation that ethanol is an inhibitor of the hCES1 enzyme 
and as hCES1 is also responsible for the metabolism of ethylphenidate [30] that 
concomitant ethanol and ethylphenidate use would lead to higher blood 
concentrations of ethylphenidate. In the course of the studies [12, 13] it was also 
determined that there are “poor” methylphenidate metabolisers in which ~100 times 
higher concentrations of methylphenidate were observed. Based on 29 subjects it is 
estimated that ~7% of people may be affected by being slow or poor metabolisers of 
methylphenidate (thought to be a CES1 null or reduced activity allelle) and may 
exhibit increased concentrations of methylphenidate compared to “normal” 
metabolisers.  
Polymorphisms have been found in hCES1 [35] but have yet to be evaluated in 
relation to metabolism of either methyl or ethylphenidate.  It is likely as the same 
enzyme metabolises both ethyl and methylphenidate that ethylphenidate would also 
be affected [30], and that concomitant administration of a drug such as heroin (which 
is also metabolised by hCES1a [30]) and other potent inhibitors of  carboxylesterase 
such as ethanol, digitonin, telmisartan [36], aripiprazole, fluoxetine [37] and 
loperamide [38] could also cause increases in the blood levels of ethylphenidate if 
taken concomitantly, potentially to fatal levels.  
These results and the literature review show that more information is required about 
both the pharmacology and toxicology of ethylphenidate in order to understand the 
effects that it has on the human body.   
  
Figure 1: Putative metabolism of ethylphenidate 
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Table 1: Ethylphenidate concentrations and cause of death 
Ethylphenidate 
concentration 
(mg/L) 
Certified  
Cause of death 
Other drugs detected 
2.18 Ethylphenidate toxicity None 
1.37 Hanging 
Benzoylecgonine = 0.012 mg/L 
Sertraline = 0.295 mg/L 
Diphenhydramine = 0.043 mg/L 
0.87 Hanging 
Dothiepin = 0.017 mg/L 
Methiopropamine = 4.640 mg/L 
Ethanol = 74 mg/100mL 
0.11 Methadone toxicity 
+ 2 amino indane toxicity 
Methadone = 0.807 mg/L 
EDDP = 0.532 mg/L 
Zopiclone = 0.123 mg/L 
Sertraline = 0.494 mg/L 
Aripiprazole = 0.073 mg/L 
Dehydroaripiprazole = 0.016 mg/L 
2-Aminoindane = 0.101 mg/L 
Ethanol = 30 mg/100ml 
0.14 Heroin toxicity 
Morphine (free) = 0.117 mg/L 
Morphine (total) = 0.180 mg/L 
Codeine (free) = 0.011 mg/L 
Ketamine = 0.518 mg/L 
Cocaine = 0.12 mg/L 
Benzoylecgonine = 0.272 mg/L 
Venlafaxine = 0.344 mg/L 
O-desmethylvenlafaxine  = 0.374 mg/L 
0.03 Mixed drug toxicity Methiopropamine = 0.051 mg/L 5APB/6APB = 1.410 mg/L 
0.11 Multiple drug toxicity 
Diazepam = 0.316 mg/L 
Nordiazepam = 0.409 mg/L 
Temazepam = 0.017 mg/L 
Oxazepam = 0.009 mg/L 
Morphine (free) = 0.071 mg/L 
Morphine (total) = 0.101 mg/L 
Codeine (free) = 0.014 mg/L 
 
  
Table 2: Ethylphenidate concentrations found in a variety of case types (clinical, 
drugs deaths, not drug related) in blood/serum/plasma 
 
Author Case Type Number of Cases Ethylphenidate 
Concentration (mg/L) 
Krueger et al.,  [18] Not drug related 2 0.023, 0.110 (femoral blood) 
 
Park et al., [6] Not drug related 6 0.010 - >2.0 (femoral blood) 
This Study Not drug related 2 0.87, 1.37 (femoral blood) 
Bailey et al., [7] Clinical overdose 1 0.24  (blood) 
Park et al., [6] Antemortem 2 0.030, 0.46 (antemortem) 
This Study Drug toxicity (not related 
to ethylphenidate) 
2 0.11, 0.14 (femoral blood) 
Park et al., [6] Drug toxicity (not related 
to ethylphenidate)  
 0.010, 0.040 (femoral blood)   
Park et al., [6] Drug toxicity (multiple) 6 0.25 - 1.9, (femoral blood) 
This Study  Drug toxicity (multiple) 2 0.03, 0.11 (femoral blood) 
This Study Ethylphendate Toxicity 1 2.2 (femoral blood) 
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